An open-label trial found that pioglitazone/metformin plus dapagliflozin did not beat basal insulin/metformin on its primary glycaemic endpoint, with secondary metabolic signals favouring the oral regimen. PICO summary and expert commentary.
Browsing: SGLT2 Inhibitors
Evidence summaries for SGLT2 inhibitors across diabetes, heart failure, chronic kidney disease, cardiovascular outcomes, renal protection, and safety.
A post hoc analysis of a 32-week randomised trial examined how semaglutide, empagliflozin and their combination altered renal diffusion-weighted MRI and total kidney volume in type 2 diabetes. PICO summary and expert commentary.
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.
An exploratory imaging substudy of a 32-week randomised trial finds semaglutide and empagliflozin each lower cortical apparent diffusion coefficient and reduce total kidney volume in type 2 diabetes. PICO summary and expert commentary.
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…